로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > NKG2A

NKG2A

Brief Information

Name:NK cell lectin-like receptor subfamily C member 1
Target Synonym:CD159a,NKG2A,KLRC1,Killer Cell Lectin Like Receptor C1,Killer Cell Lectin-Like Receptor Subfamily C, Member 1,CD159 Antigen-Like Family Member A,NKG2-1/B Activating NK Receptor,NKG2-A/B-Activating NK Receptor,NK Cell Receptor A,NKG2-A/NKG2-B Type II Integral Membrane Protein,NKG2-A/B Type II Integral Membrane Protein,Natural Killer Group Protein 2,Natural Killer Cell Lectin,C-Lectin Type II Protein,CD159a Antigen,NKG2,NKG2-B,NKG2-A
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
NKA-M52H5 Mouse Mouse NKG2A / CD159a Protein, His Tag
NKA-M52H5-structure
NKA-M52H5-sds
NKA-C5245 Cynomolgus Cynomolgus NKG2A / CD159a Protein, His Tag
NKA-C5245-structure
NKA-C5245-sds
NKA-H526c Human Human NKG2A / CD159a Protein, Fc Tag
NKA-H526c-structure
NKA-H526c-sds
NKA-H5244 Human Human NKG2A / CD159a Protein, His Tag
NKA-H5244-structure
NKA-H5244-sds
ACRO Quality

Synonym Name

NKG2A,CD159a,KLRC1,NK cell receptor A

Background

NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation, also known as KLRC1, CD159a, NK cell receptor A and NKG2-A/NKG2-B type II integral membrane protein. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. The increase in NKG2A expression might be induced by IL-10, which was present at a high level in the plasma of HCC patients. Blocking IL-10 could specifically inhibit NKG2A expression in NK cells. These findings indicate that NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion, suggesting that NKG2A blockade has the potential to restore immunity against liver tumors by reversing NK cell exhaustion.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
S-095029 S-095029 Phase 1 Clinical Institut De Recherches Internationales Servier Solid tumours Details
HY000102 HY-0102; HY-000102 Phase 1 Clinical Shanghai HyaMab Biotech Co Ltd Solid tumours Details
Monalizumab NN-8765; IPH-2201; NNC-0141-0000-0100 Phase 3 Clinical Novo Nordisk A/S, Innate Pharma Head and Neck Neoplasms; Hematologic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Arthritis, Rheumatoid; Breast Neoplasms; Genital Neoplasms, Female; Inflammation; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap